Discussion  by unknown
mechanical characteristics, which mimic those of natives
trachea.17,18 Interestingly, the immunologic and mechanical
characteristics of the matrices remained unaffected by a
2-month storage in PBS (containing 1% antibiotic and anti-
mycotic, at 4C). Moreover, higher DEM cycles (>17) are to
be avoided because they worsen the mechanical properties
of the matrices to such an extent that implantation could
be jeopardized. Undoubtedly, the DEM-generated matrices
resemble normal trachea far more than those generated by
using our previously reported protocols.5
To confirm the nonimmunogenic properties of the DEM-
generated matrices, we implanted them in HLA-unmatched
pigs and mice, mimicking allotransplantation and xenotrans-
plantation settings. Implants were left over a period of 30
days without immunosuppression. They displayed no histo-
logic signs of local or graft rejection and significantly less in-
flammatory reaction and activation of adhesion molecules
(eg, P-selectin) or expression of SLA antibodies when com-
pared with control or untreated tracheas during the study pe-
riod. One possible contributory factor to avoidance of
hyperacute and acute rejection is the lack of an immediate
dedicated blood supply, although vessels were seen to
grow into the implanted tissue with time.
In conclusion, our findings suggest that 17 cycles or
around 35 days of DEM are necessary to bioengineer a tra-
cheal tubular matrix that is structurally and mechanically
similar to native trachea. We show that higher cycles should
be avoided to maintain mechanical force and strength. The
immunologic ignorance resulting from this procedure avoids
allorejection and xenorejection in the present animal models,
and therefore there is no need for immunosuppression. We
believe this protocol opens the door to the creation of clini-
cally functional, fully tissue-engineered airway replace-
ments in the near future.
We acknowledge the assistance of Laura Morte for her excellent
organization and troubleshooting. Furthermore, we would like to
express our gratitude to Pablo Engel and Jordi Sintes for kindly pro-
viding the P-Selectin antibody. Finally, we are indebted to Victor
Peinado and others on his team for their superb assistance.
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Dr Sebastien Gilbert (Pittsburgh, Pa). First, I would like to
congratulate you and your team for your contribution to the excit-
ing field of airway replacement and regeneration.
I have 3 questions. First, in addition to uniaxial loading, have
you looked at the pressure-diameter response of the grafts or the
ability of the graft to withstand negative intraluminal pressure with-
out collapsing?
Dr Jungebluth. That is a very interesting point. We have not
done it until now but are currently in the process of doing so.
DrGilbert. Second, what effect, if any, does the 35-day, 17-cycle
detergent preparation have on the collagen fiber integrity and the gly-
cosaminoglycan content of the extracellular matrix of the trachea?
Dr Jungebluth. Actually, we did not check it immediately, but
the mechanical strain test showed that this quiet and soft and gentle
treatment actually did not have a strong effect on the mechanical
properties of this tracheal matrix if you just continued under 17 cy-
cles, but I guess it is a critical point that if you continue above 17
cycles, then you will lose the strength and the strain of this matrix.
Dr Gilbert. Finally, what are your thoughts on the relative im-
portance of cartilage and airway epithelium in the immunogenicity
of decellularized tracheal grafts?
Dr Jungebluth. I did not get it. Once again, please.
Dr Gilbert. You showed some pathology slides looking at car-
tilage after 17 detergent cycles, and you made a point to highlight
that there are probably no viable chondrocytes. Do you think thegery c September 2009
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cellular components?
Dr Jungebluth. That is a very interesting question. At this point,
we just looked for the antigenicity and for the strainability. Cur-
rently, we are investigating seeding this matrix again with isolated
cells, and we guess that now we can concentrate on the epithelial
problem with this matrix. Until now, we just finished the mechan-
ical and the antigenicity part, but we are still in the process.
Dr Macchiarini. Just to answer your last question, the role of
cartilage in this model is a minor one. It is true that there were
a few nuclei left, but that did not play any role in the immunoge-
nicity of these grafts when implanted. Therefore I think that if
you have a matrix that still has some vital cartilage, this will not
play a role in the rejection process simply because they are not
vascularized or they are not as vascularized as the internal part
of the trachea.
Dr Robert J. Cerfolio (Birmingham, Ala). First, I congratulate
Dr Macchiarini for the all the wonderful work he has accomplished
in this field. This is such a bad clinical problem. We all see patients
who have had stents put in for benign disease and then we end up
taking them out. We have patients who have had tracheal resections
who come back with anastomotic strictures and problems.
I noticed you are out 30 days. My question to you regards the
future. How much longer are you going to follow these patients
and evaluate for tracheomalacia after implantation, and how far
away are we from being able to pull this off a shelf and put it
into a human being? That would be just fantastic.
DrMacchiarini. Probably he is able to answer more than I, but I
just wanted to thank you for the nice comment.The Journal of Thoracic andWe are in the process of generating a bioreactor in which we will
be able to reseed the trachea with autologous cells—I mean chon-
drocytes—and we succeeded also in reseeding the internal surface
of the trachea with respiratory cells. Hopefully we will present this
next year or in 2 years at this congress.
Coming to your questions, we are now in the process of having
one potential patient who would need a replacement. After the eth-
ical commission and so forth, what we did is take off cartilage from
the nasal septum and from the respiratory cells of the trachea and
put it in culture, and therefore we needed to reseed a donor trachea
that was treated with the DEM procedures. This last process takes
approximately 1 week. Harvesting the donor, depending on the do-
nor pool, and then preparing these cycles takes approximately 11ˇ/2
months. Therefore it would be an elective procedure that we can
prepare, at best, for not only the implantation but even for the char-
acteristics of the graft. I think that 1 to 2 months will be fine to have
an ideal individualized human trachea.
Dr Yolonda L. Colson (Boston, Mass). My concern would be
ciliary clearance. Because there is not anything that looks like cilia,
how are you going to get it to clear the secretions, or do you think it
is going to regrow and repopulate across it?
Dr Macchiarini. That is a wonderful question. Again, hope-
fully, we will present the data. We went a step further and per-
formed orthotopic transplantation of 6 cm in pigs in which we
showed as soon as day 4 that there were ciliary activities. The Bos-
ton and Toronto group showed clearly that as long as you have
a 4-cm graft, there will be some migration of adherent cells. Six
centimeters is clinically more important than 4 cm, but I do not
think that will change this migration capacity.Cardiovascular Surgery c Volume 138, Number 3 593
